Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that the Japanese Patent Office has issued the notice of ...
Morningstar

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα ...

BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second ...
Business Wire

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development ...